SEC Form 4 · accession 0000899243-17-016999
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark L Perry
Director
Period of report
Jun 20, 2017
Accepted (ET)
Jun 22, 2017 · 9:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $28.45 | Jun 20, 2017 | A | 15,000 | A | — | Jun 19, 2027 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1The shares vest and become exercisable in 12 equal monthly installments, with the first installment on July 20, 2017, subject to the recipient's continued service on the Issuer's Board of Directors. This option is subject to accelerated vesting upon a change of control of the Issuer.